We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue
Read MoreHide Full Article
Mallinckrodt plc announced that its subsidiary, Stratatech, has completed the rolling submission of a biologics license application (BLA) for its investigational product, StrataGraft a regenerative skin tissue to treat deep partial-thickness thermal burns.
The BLA is based on data from the pivotal phase III STRATA2016 and the STRATA2011 clinical studies. We remind investors that in September 2019, Mallinckrodt announced positive top-line results from the pivotal STRATA2016 study on StrataGraft regenerative skin tissue for the treatment of deep partial-thickness thermal burns. The study, which met both primary endpoints, evaluated the efficacy and safety of a single application of StrataGraft regenerative skin tissue for the given indication.
Shares of Mallinckrodt have lost 14.1% so far this year compared with the industry’s decline of 0.7%.
The FDA granted StrataGraft skin tissue the Orphan Drug status in 2012 for the treatment of partial and full-thickness skin burns.
Notably, the Orphan Drug designation is granted to drugs that are capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses and an exemption from the FDA user fee.
Mallinckrodt also plans to evaluate StrataGraft skin tissue for the treatment of adults with full-thickness burns (also known as third-degree burns). Further, the company plans to evaluate StrataGraft skin tissue for treating pediatric patients.
Meanwhile, in March 2020, Mallinckrodt completed the rolling submission of the new drug application (NDA) seeking approval for its pipeline candidate, terlipressin, as a treatment for hepatorenal syndrome type 1 (HRS-1). This life-threatening syndrome involves acute kidney failure in cirrhosis patients.
Terlipressin is not approved for any indication in the United States and Canada. A potential approval of the candidate in the United States will be a huge boost for the company.
Adamas’ loss per share estimates have narrowed 1.4% for 2020 over the past 60 days.
Assembly Biosciences’ loss per share estimates have narrowed 20.6% for 2020 and 16.38% for 2021 over the past 60 days.
Amphastar’s earnings per share estimates have increased 3.7% for 2020 over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue
Mallinckrodt plc announced that its subsidiary, Stratatech, has completed the rolling submission of a biologics license application (BLA) for its investigational product, StrataGraft a regenerative skin tissue to treat deep partial-thickness thermal burns.
The BLA is based on data from the pivotal phase III STRATA2016 and the STRATA2011 clinical studies. We remind investors that in September 2019, Mallinckrodt announced positive top-line results from the pivotal STRATA2016 study on StrataGraft regenerative skin tissue for the treatment of deep partial-thickness thermal burns. The study, which met both primary endpoints, evaluated the efficacy and safety of a single application of StrataGraft regenerative skin tissue for the given indication.
Shares of Mallinckrodt have lost 14.1% so far this year compared with the industry’s decline of 0.7%.
The FDA granted StrataGraft skin tissue the Orphan Drug status in 2012 for the treatment of partial and full-thickness skin burns.
Notably, the Orphan Drug designation is granted to drugs that are capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses and an exemption from the FDA user fee.
Mallinckrodt also plans to evaluate StrataGraft skin tissue for the treatment of adults with full-thickness burns (also known as third-degree burns). Further, the company plans to evaluate StrataGraft skin tissue for treating pediatric patients.
Meanwhile, in March 2020, Mallinckrodt completed the rolling submission of the new drug application (NDA) seeking approval for its pipeline candidate, terlipressin, as a treatment for hepatorenal syndrome type 1 (HRS-1). This life-threatening syndrome involves acute kidney failure in cirrhosis patients.
Terlipressin is not approved for any indication in the United States and Canada. A potential approval of the candidate in the United States will be a huge boost for the company.
Mallinckrodt public limited company Price
Mallinckrodt public limited company price | Mallinckrodt public limited company Quote
Zacks Rank & Stocks to Consider
Mallinckrodt currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the healthcare sector include Adamas Pharmaceuticals, Inc. , Assembly Biosciences Inc. (ASMB - Free Report) , and Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) , all sporting a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Adamas’ loss per share estimates have narrowed 1.4% for 2020 over the past 60 days.
Assembly Biosciences’ loss per share estimates have narrowed 20.6% for 2020 and 16.38% for 2021 over the past 60 days.
Amphastar’s earnings per share estimates have increased 3.7% for 2020 over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>